Genetic principles enabling the creation of bacteria-based therapeutics
Abstract
Genetic engineering can transform bacteria (including Salmonella, Escherichia coli, Listeria, and Yersinia) from naturally occurring microbes into programmable therapeutics. Unlike passive platforms, engineered bacteria can localize to defined biological niches, sense environmental cues, regulate programmed activity in situ, interact with host tissues in novel ways, and persist for controlled periods. These properties make bacteria versatile medicines but require genetic control of precision, safety, stability, and activity under clinical conditions. Major design layers include strain or “chassis” selection, attenuation and biocontainment, control of therapeutic activity, targeting and persistence, and genotype-to-phenotype stability during manufacturing and in vivo use. These features also create liabilities, including off-target behavior, unstable expression, and evolutionary loss of function under selection. Progress depends on safe, clinically translatable chassis with integrated, bounded, and durable behaviors. This review examines the genetic design principles and liabilities of bacteria-based therapeutics, approaches used to produce clinical and near-clinical candidates, and the emergence of programmed bacteria delivering complete gene editing systems to therapeutically relevant cells.
Related
- Engineering Persistent and Rewritable Genetic Memory in Bacteria through Multiscale Plasmid Competition
- A panel of Diversity Outbred mouse embryonic stem cells: enabling the functional characterization of natural genetic variation in vitro
- Sum-h2, enabling genetic discovery for deep learning-derived phenotypes through a fast evaluation framework and arena of performance
- BRIDGE: A broad-host platform for interkingdom DNA delivery enabling the genetic domestication of phylogenetically diverse yeasts
- In situ genetic modification of gut bacteria
BibTeX
@article{williams2026genetic,
title = {{Genetic principles enabling the creation of bacteria-based therapeutics}},
author = {Ashley B Williams and Thomas M Groseclose and Sara A M Holec and Darrian Newman and Darcy S O Mora and Lyndsey Linke},
journal = {Genetics},
year = {2026},
month = sep,
doi = {10.1093/genetics/iyag235},
url = {https://doi.org/10.1093/genetics/iyag235},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Genetic principles enabling the creation of bacteria-based therapeutics
AU - Ashley B Williams
AU - Thomas M Groseclose
AU - Sara A M Holec
AU - Darrian Newman
AU - Darcy S O Mora
AU - Lyndsey Linke
PY - 2026
DA - 2026/09/17
JO - Genetics
DO - 10.1093/genetics/iyag235
UR - https://doi.org/10.1093/genetics/iyag235
AB - Genetic engineering can transform bacteria (including Salmonella, Escherichia coli, Listeria, and Yersinia) from naturally occurring microbes into programmable therapeutics. Unlike passive platforms, engineered bacteria can localize to defined biological niches, sense environmental cues, regulate programmed activity in situ, interact with host tissues in novel ways, and persist for controlled periods. These properties make bacteria versatile medicines but require genetic control of precision, safety, stability, and activity under clinical conditions. Major design layers include strain or “chassis” selection, attenuation and biocontainment, control of therapeutic activity, targeting and persistence, and genotype-to-phenotype stability during manufacturing and in vivo use. These features also create liabilities, including off-target behavior, unstable expression, and evolutionary loss of function under selection. Progress depends on safe, clinically translatable chassis with integrated, bounded, and durable behaviors. This review examines the genetic design principles and liabilities of bacteria-based therapeutics, approaches used to produce clinical and near-clinical candidates, and the emergence of programmed bacteria delivering complete gene editing systems to therapeutically relevant cells.
SN - 0016-6731
SN - 1943-2631
ER -